232 related articles for article (PubMed ID: 27258009)
1. Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.
Jeong BY; Uddin MJ; Park JH; Lee JH; Lee HB; Miyata T; Ha H
PLoS One; 2016; 11(6):e0157012. PubMed ID: 27258009
[TBL] [Abstract][Full Text] [Related]
2. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney.
Lee EA; Seo JY; Jiang Z; Yu MR; Kwon MK; Ha H; Lee HB
Kidney Int; 2005 May; 67(5):1762-71. PubMed ID: 15840023
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.
Nicholas SB; Aguiniga E; Ren Y; Kim J; Wong J; Govindarajan N; Noda M; Wang W; Kawano Y; Collins A; Hsueh WA
Kidney Int; 2005 Apr; 67(4):1297-307. PubMed ID: 15780082
[TBL] [Abstract][Full Text] [Related]
4. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
Nicholas SB; Kawano Y; Wakino S; Collins AR; Hsueh WA
Hypertension; 2001 Feb; 37(2 Pt 2):722-7. PubMed ID: 11230363
[TBL] [Abstract][Full Text] [Related]
5. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Huang Y; Border WA; Yu L; Zhang J; Lawrence DA; Noble NA
J Am Soc Nephrol; 2008 Feb; 19(2):329-38. PubMed ID: 18216319
[TBL] [Abstract][Full Text] [Related]
6. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.
Rossini M; Naito T; Yang H; Freeman M; Donnert E; Ma LJ; Dunn SR; Sharma K; Fogo AB
Nephrol Dial Transplant; 2010 Jun; 25(6):1803-10. PubMed ID: 20061322
[TBL] [Abstract][Full Text] [Related]
7. Effects of uPA on mesangial matrix changes in the kidney of diabetic rats.
Cheng H; Chen C; Wang S
Ren Fail; 2014 Sep; 36(8):1322-7. PubMed ID: 25010090
[TBL] [Abstract][Full Text] [Related]
8. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
Zhang M; Liu M; Xiong M; Gong J; Tan X
J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 and diabetic nephropathy.
Lee HB; Ha H
Nephrology (Carlton); 2005 Oct; 10 Suppl():S11-3. PubMed ID: 16174279
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.
Collins SJ; Alexander SL; Lopez-Guisa JM; Cai X; Maruvada R; Chua SC; Zhang G; Okamura DM; Matsuo S; Eddy AA
Nephron Exp Nephrol; 2006; 104(1):e23-34. PubMed ID: 16735799
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease.
Lassila M; Fukami K; Jandeleit-Dahm K; Semple T; Carmeliet P; Cooper ME; Kitching AR
Diabetologia; 2007 Jun; 50(6):1315-26. PubMed ID: 17415547
[TBL] [Abstract][Full Text] [Related]
12. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Fujisawa G; Okada K; Muto S; Fujita N; Itabashi N; Kusano E; Ishibashi S
Kidney Int; 2004 Oct; 66(4):1493-502. PubMed ID: 15458443
[TBL] [Abstract][Full Text] [Related]
14. [Protective effects and mechanisms of xin'ganbao capsule on STZ induced early kidney injury in diabetic rats].
Gao J; Fan L; Liu MJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Apr; 32(4):530-6. PubMed ID: 22803438
[TBL] [Abstract][Full Text] [Related]
15. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Yu X; Li C; Li X; Cai L
Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
[TBL] [Abstract][Full Text] [Related]
17. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models.
Hagiwara H; Kaizu K; Uriu K; Noguchi T; Takagi I; Qie YL; Seki T; Ariga T
Thromb Res; 2003; 111(4-5):301-9. PubMed ID: 14693179
[TBL] [Abstract][Full Text] [Related]
18. An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.
Gu C; Zhang J; Noble NA; Peng XR; Huang Y
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F852-F863. PubMed ID: 27511457
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.
Chen LL; Zhang JY; Wang BP
Vascul Pharmacol; 2006 May; 44(5):309-15. PubMed ID: 16624630
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
